BioSpace News Archive

InMode Ltd. today announced that Moshe Mizrahy , Chairman and Chief Executive Officer, Yair Malca , Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present virtually at the 25th Annual Needham Growth Conference on Jan. 12, 2023.

Rejuvenate Bio, today announced the appointment of Deborah Ascheim, M.D., as Chief Medical Officer.

ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the appointment of Lara Barghout as President and Chief Executive Officer of ReCor.

ReCode Therapeutics today announced that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a company overview at 9:00 a.m. PT on Tuesday, January 10, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.

PharmaEssentia Corporation today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.

Ashvattha Therapeutics today announced that the Company will provide a corporate overview at Biotech Showcase 2023 taking place in San Francisco, California, from January 9-11, 2023.

Sisram Medical Ltd today announced that it will present virtually at the 25th Annual Needham Growth Conference on Thursday, January 12, 2023.

Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics , Inc. (EVOQ) today announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus.

Masimo announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluated the accuracy of noninvasive, continuous hemoglobin monitoring with Masimo SpHb® on patients undergoing elective cesearan section with antepartum hemorrhage.

HUTCHMED Limited announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia in China.